CARD 14 Inhibitors

Inhibitors of CARD 14, also known as Caspase Recruitment Domain-containing protein 14 inhibitors, encompass a range of compounds that indirectly affect the protein's function by targeting signaling pathways involved in its regulation. CARD 14 is a key regulator of NF-κB signaling, a pathway crucial for the control of immune and inflammatory responses. The chemical inhibitors listed above are not specific to CARD 14 but are known to modulate the NF-κB pathway, which is closely tied to the functionality of CARD 14.

The inhibition of NF-κB signaling can lead to reduced transcription of pro-inflammatory cytokines and other mediators that are upregulated in conditions where CARD 14 is overactive. Chemicals like BAY 11-7082 and Parthenolide disrupt the phosphorylation and degradation of IκBα, an inhibitor of NF-κB, thereby preventing the translocation of NF-κB to the nucleus and the subsequent transcription of target genes. Others, such as TPCA-1 and IMD-0354, target IKKβ, a kinase that is critical for the activation of NF-κB. By inhibiting IKKβ, these compounds prevent the initiation of the signaling cascade that leads to NF-κB activation. Additionally, compounds like Andrographolide and Curcumin have been shown to modify key molecules within the NF-κB pathway, thereby altering the inflammatory response. Proteasome inhibitors such as MG-132 and Bortezomib affect the degradation of proteins involved in the NF-κB pathway, which in turn can influence CARD 14's signaling. Resveratrol is known to impact NF-κB signaling through various mechanisms, including the modulation of kinase activity and the alteration of gene expression.